Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880852 | 0.92 | MAPT (0.40) | GRIN2BPDE4AHRH3TLR4TLR9 | |
| SCHEMBL419640 | 0.85 | HRH3 (0.42) | HRH3IRAK4ALDH1A1NPC1POLB | |
| SCHEMBL10176637 | 0.85 | HRH3 (0.42) | GRIN2BHRH3TLR4TLR9TLR8 | |
| SCHEMBL420920 | 0.83 | HRH3 (0.42) | HRH3IRAK4ALDH1A1NPC1POLB | |
| SCHEMBL420214 | 0.83 | IRAK4 (0.44) | HRH3IRAK4ALDH1A1NPC1POLB | |
| SCHEMBL421675 | 0.82 | HRH3 (0.42) | HRH3ALDH1A1NPC1POLBMAPT | |
| SCHEMBL418639 | 0.82 | PDE4A (0.39) | PDE4AHRH3CYP11B2KCNH2 | |
| SCHEMBL419617 | 0.81 | MAT2A (0.38) | HRH3TLR4TLR9TLR8TLR7 | |
| SCHEMBL419887 | 0.81 | HRH3 (0.48) | HRH3IRAK4ALDH1A1NPC1POLB | |
| SCHEMBL7891067 | 0.81 | KDM2B (0.39) | HRH3TLR4TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2396327-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | GRIN2B 57/4885PDE4A 1366/4885HRH3 1/4885 |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | GRIN2B 57/4885PDE4A 1366/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.